TY - JOUR
T1 - Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction
T2 - A systematic review and meta-analysis of randomized controlled trials
AU - Abdel-Latif, Ahmed
AU - Bolli, Roberto
AU - Zuba-Surma, Ewa K.
AU - Tleyjeh, Imad M.
AU - Hornung, Carlton A.
AU - Dawn, Buddhadeb
N1 - Funding Information:
This meta-analysis and publication was supported in part by National Institutes of Health grants R01 HL-72410, HL-55757, HL-68088, HL-70897, HL-76794, and HL-78825.
PY - 2008/8
Y1 - 2008/8
N2 - Background: Small clinical studies of granulocyte colony-stimulating factor (G-CSF) therapy for cardiac repair after acute myocardial infarction (MI) have yielded divergent results. The effect of G-CSF therapy on left ventricular (LV) function and structure in these patients remains unclear. Methods: We searched MEDLINE, EMBASE, Science Citation Index, CINAHL, and the Cochrane CENTRAL database of controlled clinical trials (July 2007) for randomized controlled trials of G-CSF therapy in patients with acute MI. We conducted a fixed-effects meta-analysis across 8 eligible studies (n = 385 patients). Results: Compared with controls, G-CSF therapy increased LV ejection fraction (EF) by 1.09%, increased LV scar size by 0.22%, decreased LV end-diastolic volume by 4.26 mL, and decreased LV end-systolic volume by 2.50 mL. None of these effects were statistically significant. The risk of death, recurrent MI, and in-stent restenosis was similar in G-CSF-treated patients and controls. Subgroup analysis revealed a modest but statistically significant increase in EF (4.73%, P < .0001) with G-CSF therapy in studies that enrolled patients with mean EF <50% at baseline. Subgroup analysis also showed a significant increase in EF (4.65%, P < .0001) when G-CSF was administered relatively early (≤37 hours) after the acute event. Conclusions: Granulocyte colony-stimulating factor therapy in unselected patients with acute MI appears safe but does not provide an overall benefit. Subgroup analyses suggest that G-CSF therapy may be salutary in acute MI patients with LV dysfunction and when started early. Larger randomized studies may be conducted to evaluate the potential benefits of early G-CSF therapy in acute MI patients with LV dysfunction.
AB - Background: Small clinical studies of granulocyte colony-stimulating factor (G-CSF) therapy for cardiac repair after acute myocardial infarction (MI) have yielded divergent results. The effect of G-CSF therapy on left ventricular (LV) function and structure in these patients remains unclear. Methods: We searched MEDLINE, EMBASE, Science Citation Index, CINAHL, and the Cochrane CENTRAL database of controlled clinical trials (July 2007) for randomized controlled trials of G-CSF therapy in patients with acute MI. We conducted a fixed-effects meta-analysis across 8 eligible studies (n = 385 patients). Results: Compared with controls, G-CSF therapy increased LV ejection fraction (EF) by 1.09%, increased LV scar size by 0.22%, decreased LV end-diastolic volume by 4.26 mL, and decreased LV end-systolic volume by 2.50 mL. None of these effects were statistically significant. The risk of death, recurrent MI, and in-stent restenosis was similar in G-CSF-treated patients and controls. Subgroup analysis revealed a modest but statistically significant increase in EF (4.73%, P < .0001) with G-CSF therapy in studies that enrolled patients with mean EF <50% at baseline. Subgroup analysis also showed a significant increase in EF (4.65%, P < .0001) when G-CSF was administered relatively early (≤37 hours) after the acute event. Conclusions: Granulocyte colony-stimulating factor therapy in unselected patients with acute MI appears safe but does not provide an overall benefit. Subgroup analyses suggest that G-CSF therapy may be salutary in acute MI patients with LV dysfunction and when started early. Larger randomized studies may be conducted to evaluate the potential benefits of early G-CSF therapy in acute MI patients with LV dysfunction.
UR - http://www.scopus.com/inward/record.url?scp=47649087935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47649087935&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2008.03.024
DO - 10.1016/j.ahj.2008.03.024
M3 - Article
C2 - 18657649
AN - SCOPUS:47649087935
SN - 0002-8703
VL - 156
SP - 216-226.e9
JO - American Heart Journal
JF - American Heart Journal
IS - 2
ER -